Results 21 to 30 of about 9,913 (182)

Strong Association between Inotrope Administration and Intraventricular Hemorrhage, Gestational Age, and the Use of Fentanyl in Very Low Gestational Age Infants: A Retrospective Study

Children, 2023
This was a single center, retrospective cohort study designed to evaluate the association between the administration of inotropes to hypotensive very low gestational age infants (VLGAI) and prenatal and neonatal risk factors.
Theodora Stathopoulou, Eleni Agakidou, Christos Paschaloudis, Angeliki Kontou, Ilias Chatzioannidis, Kosmas Sarafidis   +5 more
doaj   +1 more source

Angiotensin receptor neprilysin inhibitor in inotrope dependent heart failure patients: A case series [PDF]

Journal of Cardiovascular and Thoracic Research, 2020
Patients with advanced heart failure (HF) symptoms constitute stage D heart failure with high mortality and less response to conventional guideline directed medical therapies.
Sepideh Taghavi, Maryam Chenaghlou, Marzieh Mirtajaddini, Ahmad Amin, Nasim Naderi   +4 more
doaj   +1 more source

Implications of Myocardial Infarction on Management and Outcome in Cardiogenic Shock

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background The randomized DOREMI (Dobutamine Compared to Milrinone) clinical trial evaluated the efficacy and safety of milrinone and dobutamine in patients with cardiogenic shock. Whether the results remain consistent when stratified by acute myocardial
Richard G. Jung, Pietro Di Santo, Rebecca Mathew, Omar Abdel‐Razek, Simon Parlow, Trevor Simard, Jeffrey A. Marbach, Taylor Gillmore, Brennan Mao, Jordan Bernick, Pascal Theriault‐Lauzier, Angel Fu, Lawrence Lau, Pouya Motazedian, Juan J. Russo, Marino Labinaz, Benjamin Hibbert   +16 more
doaj   +1 more source

Vasopressors and inotropes in cardiogenic shock patients: an analysis of the MIMIC-IV database

Frontiers in Cardiovascular Medicine, 2023
IntroductionPharmacological support has become the mainstay therapy in patients with cardiogenic shock (CS). Unfortunately, the clinical benefits of such potent drugs remain unclear, therefore, the present study aims to elucidate the safety and efficacy ...
Bryan Richard Sasmita, ChuanYing Wang, Siyuan Xie   +2 more
doaj   +1 more source

Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (−)‐noradrenaline

Pharmacology Research & Perspectives, 2021
Omecamtiv mecarbil (OM) is a novel medicine for systolic heart failure, targeting myosin to enhance cardiomyocyte performance. To assist translation to clinical practice we investigated OMs effect on explanted human failing hearts, specifically ...
Alexander Dashwood, Elizabeth Cheesman, Yee Weng Wong, Haris Haqqani, Nicole Beard, Karen Hay, Melanie Spratt, Wandy Chan, Peter Molenaar   +8 more
doaj   +1 more source

Coronary Slow Flow and No‐Reflow During Percutaneous Coronary Intervention: Contemporary Insights Into Imaging‐Guided Prediction, Prevention, and Management

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Coronary slow flow (SF) and no‐reflow (NR) are clinically significant complications of percutaneous coronary intervention (PCI), particularly in ST‐segment elevation myocardial infarction (STEMI) and saphenous vein graft (SVG) interventions. Angiographically defined as impaired myocardial perfusion despite restored epicardial patency, SF/NR ...
Bharat Khialani, Eran Sim, George Touma, Sarah Fairley, Cuneyt Ada, Bernard Wong   +5 more
wiley   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Investigation of Impact of Trinitroglycerin Conjugated Cardioplegia on Myocardial Protection of Patients With Coronary Artery Bypass Grafting

Acta Medica Iranica, 2020
Pharmacologic-conjugated-cardioplegia is one of the strategies against ischemia and reperfusion. The aim of this study was to investigate the impact of nitroglycerin on myocardial protection and postoperative outcomes.
Mohammad Hasan Nemati, Hasan Badie, Mansour Jannati   +2 more
doaj   +1 more source

Clinical efficacy of levosimendan vs milrinone in preventing low cardiac output syndrome following pediatric cardiac surgery

Annals of Cardiac Anaesthesia, 2021
Background: Prophylactic milrinone is commonly used to prevent Low Cardiac Output Syndrome (LCOS) after pediatric cardiac surgery. This study compares the use of levosimendan with milrinone when used as the primary inotrope following pediatric cardiac ...
Kaushik Jothinath, Soundaravalli Balakrishnan, Vijayakumar Raju, Shoba Menon, Jenit Osborn   +4 more
doaj   +1 more source

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source